Skip to content
Head to head

Immunovant vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: IMVT · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

IMVT +30.7%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
IMVTVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price31.77515.02
Change today-2.31%-1.08%
1-year return+39.4%+22.0%
Market cap$6.57B$130.58B
52-week range21.93 – 45.42412.27 – 568.67
Valuation
P/E (TTM)-12.4133.14
P/E percentile, own 5-yr range28th99th
P/B10.016.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.7715.32
Net profit (TTM)$-573.25M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-395.01M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership113.3%96.8%
Insider activity (12mo)17 buy / 33 sell28 buy / 22 sell
Short interest (% of float)9.0%1.9%
Analyst consensus75% buy / 25% hold (8)95% buy / 5% hold (21)
Analyst price target$48 (+52%)$624 (+21%)
StockVane view
StockVane Quant RatingD (81)C (68)
Company
Employees3156,400
Founded20181989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.